U.S. Genome Editing Industry

The U.S. genome editing market size was estimated at USD 3.49 billion in 2023 and is expected to grow at a CAGR of 16.5% from 2024 to 2030. The growth in the genome editing market is driven by rising demand for synthetic genes, the application of CRISPR technology, and government funding. The expansion is further fueled by the production of genetically modified crops, genomics projects, and advancements in research and development. Innovative gene editing methods have advanced gene therapy and molecular biology significantly. The availability of user-friendly gene therapy systems and the potential for rapid genome-wide analyses also contribute to the market growth.

The U.S. accounted for over 43.9% of the global genome editing market in 2023. The advent of innovative technologies enabling easy editing of genomic DNA has unlocked a transformative period in therapeutic development. Genome editing technology has the potential to take precision medicine to the next level. Anticipated regulatory approvals for research and clinical trials involving gene editing therapies will likely boost their acceptance soon. Successful outcomes in preclinical and phase I clinical trials are projected to impact product introductions and stimulate market growth with promising opportunities.

Gather more insights about the market drivers, restrains and growth of the U.S. Genome Editing market

In recent years, the market has expanded primarily due to the rising demand for synthetic genes and the increased use of CRISPR genome editing technology in various biotech sectors. The growth is expected to be propelled by increased government funding, a surge in the production of genetically modified crops, and a rise in genomics projects. CRISPR-based diagnostic tools, instrumental in COVID-19 diagnostics, also drive this growth. For example, the VaNGuard (Variant Nucleotide Guard) diagnostic test, developed by academics from Nanyang Technological University in March 2021, can identify mutated SARS-CoV-2 strains, thereby enhancing the use of CRISPR genome editing technology in the diagnostics sector.

Furthermore, ongoing advancements in gene-editing technologies significantly contribute to the market’s profitability. For instance, scientists at Harvard’s Wyss Institute for Biologically Inspired Engineering developed a new gene-editing tool called Retron Library Recombineering (RLR) in April 2021. This tool enables the execution of millions of genetic experiments simultaneously, thereby enhancing editing rates. The market expansion is driven by supportive government policies concerning synthetic biology, a growing demand for engineered genes and cells, and increased government and major corporations investments.

Developing and applying novel gene-editing techniques have marked significant progress in gene therapy and molecular biology, further propelling the market’s growth. In addition, the market growth during the projected period is fueled by the availability of easy-to-use gene therapy systems, progress in genome engineering, and the ability of gene therapy to expedite comprehensive analyses of gene function across the genome. Although gene editing technologies are confined to the basic research area in drug development, they hold great potential for detecting and validating new therapeutic targets. It also plays a great role in understanding a drug’s mechanism of action by providing a broader picture of genes involved in regulating various cell biological processes.

Key U.S. Genome Editing Company Insights

Companies in the U.S. genome editing industry are entering into licensing agreements with technology developers to strengthen their presence in the market. Key industry participants actively pursue strategic actions such as acquisitions, partnerships, and collaborations to optimize their market share. For instance, in April 2022, Thermo Fisher Scientific introduced the Gibco CTS TrueCut Cas9 Protein, a top-tier support material for researchers transitioning from basic research to therapeutic applications utilizing genome editing techniques. This product shows promise for studying CAR T-cell therapies through CRISPR-Cas9 genome editing, consistently demonstrating over 90% efficacy in human primary T-cells and high editing efficiency across various cell lines.

Key U.S. Genome Editing Companies:

  • Merck KGaA
  • Cibus
  • Recombinetics, Inc.
  • Sangamo
  • Editas Medicine
  • Precision Biosciences
  • CRISPR Therapeutics
  • Intellia Therapeutics, Inc.
  • Caribou Biosciences, Inc.
  • Cellectis S.A.
  • GenScript
  • AstraZeneca
  • Integrated DNA Technologies, Inc.
  • Egenesis Inc.
  • New England Biolabs
  • OriGene Technologies, Inc.
  • Lonza
  • Thermo Fisher Scientific, Inc.

Recent Developments

  • In February 2024, Precision BioSciences, Inc. (Nasdaq: DTIL), specializing in advanced gene editing, uses its unique ARCUS platform to create in-vivo treatments. These treatments involve complex gene modifications, including insertion, removal, and deletion.
  • In November 2023, AstraZeneca Holding B.V. and Cellectis initiated a collaborative research project. This collaboration aims to utilize Cellectis' gene editing and production expertise to expedite the creation of advanced treatments. These treatments are primarily targeted towards areas with a significant lack of adequate solutions, such as cancer, immunology, and rare diseases.
  • In January 2023, Editas Medicine finalized a contract with Shoreline Biosciences, as per which Shoreline Biosciences takes over Editas Medicine's preclinical programs. These programs involve gene-edited induced pluripotent stem cells (iPSC) that are developed into natural killer cells (iNK), including the EDIT-202 program. The agreement also includes the transfer of related manufacturing technologies.

Order a free sample PDF of the U.S. Genome Editing Market Intelligence Study, published by Grand View Research.